BLEEDnFIRE Therapeutics
Ittingen
About BLEEDnFIRE Therapeutics
BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $170.0K
- Last round: Grant (Nov 2024)
- Website: venturekick.chbleednfire-therapeutics
Canonical: https://fsome.com/organization/bleednfire-therapeutics-123417 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.